LigaChem Biosciences Inc. Logo

LigaChem Biosciences Inc.

Clinical-stage biopharma developing ADCs, immuno-oncology drugs, and small molecules.

141080 | KO

Overview

Corporate Details

ISIN(s):
KR7141080002
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학10로 10 (주)레고켐 바이오사이언스, 대전광역시

Description

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-11-22 00:00
기업설명회(IR)개최
Korean 6.9 KB
2024-11-18 00:00
투자판단관련주요경영사항 (LCB97 관련 마일스톤 기술료 수령)
Korean 7.8 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.2 MB
2024-10-14 00:00
주요사항보고서(자기주식취득신탁계약체결결정)
Korean 26.9 KB
2024-10-10 00:00
투자판단관련주요경영사항 (LCB97(L1CAM-ADC,항체-약물 결합체)대상 기술이전계약 체결)
Korean 10.9 KB
2024-10-10 00:00
투자판단관련주요경영사항 (항체-약물 복합체(ADC) 멀티타겟 대상 공동연구 및 원천기술 기술이전계약 체결)
Korean 10.2 KB
2024-10-07 00:00
주식등의대량보유상황보고서(약식)
Korean 55.7 KB
2024-08-19 00:00
기업설명회(IR)개최
Korean 6.8 KB
2024-08-14 00:00
반기보고서 (2024.06)
Korean 1.4 MB
2024-07-01 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 20.9 KB
2024-07-01 00:00
주식등의대량보유상황보고서(일반)
Korean 107.2 KB
2024-06-19 00:00
기업설명회(IR)개최
Korean 6.7 KB
2024-05-21 00:00
주식매수선택권부여에관한신고
Korean 12.9 KB
2024-05-16 00:00
[기재정정]분기보고서 (2024.03)
Korean 1.5 MB
2024-05-13 00:00
분기보고서 (2024.03)
Korean 1.4 MB

Automate Your Workflow. Get a real-time feed of all LigaChem Biosciences Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for LigaChem Biosciences Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for LigaChem Biosciences Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.